IgA nephropathy medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{IgA nephropathy  }}
{{IgA nephropathy  }}
{{CMG}}{{APM}} {{AE}}{{OO}]
{{CMG}}; {{AE}}{{OO}}, {{APM}}  


==[[IgA nephropathy|Medical Therapy]]==
==[[IgA nephropathy|Medical Therapy]]==
Line 53: Line 53:
{{WH}}
{{WH}}
{{WS}}
{{WS}}


[[Category:Nephrology]]
[[Category:Nephrology]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]

Latest revision as of 12:54, 20 July 2018

IgA nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating IgA nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

IgA nephropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of IgA nephropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on IgA nephropathy medical therapy

CDC on IgA nephropathy medical therapy

IgA nephropathy medical therapy in the news

Blogs on IgA nephropathy medical therapy

Directions to Hospitals Treating IgA nephropathy

Risk calculators and risk factors for IgA nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[2], Ali Poyan Mehr, M.D. [3]

Medical Therapy

According to “The National Kidney Foundation: Kidney Disease - Improving Global Outcomes” (NKF-KDIGO)[1] in 2012, the management and treatment recommendations of primary IgA nephropathy are as follows:

Goals of Management

Treatment

Supportive Measures

Supportive measures are to performed in IgA nephropathy similar to the measures required for management of ATN[2]

  • Indication: Remarkable presence of only ATN and intratubular RBC casts

Pharmacologic Therapy

ACE-I or ARB are helpful to reduce proteinuria. Nonetheless, randomized clinical trials (RCT) have not yet been conducted to assess their role in reducing the progression to ESRD. Although combination therapy has been proven more effective in monotherapy in some studies[4][5], KDIGO guidelines have not made recommendations about combination therapy yet pending RCTs.

The use of steroids in patient with a GFR<50 ml/min/1.73m2 has not been studied yet. Specific dosage is not yet recommended according to KDIGO guidelines. There are more observed side-effects with high-dose pulse corticosteroids.

Immunosuppressive agents should not be used in patients with low GFR < 30 ml/min/1.73m2 except if indicated as above. The dose of steroid must be reduced when using concomitant immunosuppressive therapy. One RCT showed better kidney function by reducing corticosteroid dose from 40mg/d to 10mg/d with use of cyclophosphamide at 1.5mg/kg/d for 3 months followed by azathioprine at 1.5mg/kg/d for at least 2 years.

Fish oil at a dose of 12g/d was shown to improve renal outcome in patients with IgA nephropathy in trials by reducing rate of ESRD in 4 years from 40% to only 4%.[6] In another 6-month study, 3g/d dose also showed better prognosis with less proteinuria.[7]

References

  1. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J; et al. (2005). "Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy". Kidney Int. 67 (6): 2313–20. doi:10.1111/j.1523-1755.2005.00335.x. PMID 15882273.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Radhakrishnan J, Cattran DC (2012). "The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient". Kidney Int. 82 (8): 840–56. doi:10.1038/ki.2012.280. PMID 22895519.
  3. Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry (2007). "Remission of proteinuria improves prognosis in IgA nephropathy". J Am Soc Nephrol. 18 (12): 3177–83. doi:10.1681/ASN.2007050526. PMID 17978307.
  4. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M; et al. (1999). "Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy". Am J Kidney Dis. 33 (5): 851–6. PMID 10213639.
  5. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A; et al. (2005). "Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy". Clin Nephrol. 64 (1): 35–40. PMID 16047643.
  6. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE (1994). "A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group". N Engl J Med. 331 (18): 1194–9. doi:10.1056/NEJM199411033311804. PMID 7935657.
  7. Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC (1999). "The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group". J Am Soc Nephrol. 10 (8): 1772–7. PMID 10446945.

Template:WH Template:WS